218 related articles for article (PubMed ID: 37022356)
21. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.
Maloney NJ; Ravi V; Cheng K; Bach DQ; Worswick S
Int J Dermatol; 2020 Jun; 59(6):e183-e188. PubMed ID: 32052409
[TBL] [Abstract][Full Text] [Related]
22. [Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor-related skin adverse reactions (2024 edition)].
; ;
Zhonghua Yi Xue Za Zhi; 2024 May; 104(20):1790-1803. PubMed ID: 38782747
[TBL] [Abstract][Full Text] [Related]
23. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis.
Hadavand MA; Kaffenberger B; Cartron AM; Trinidad JCL
J Am Acad Dermatol; 2022 Sep; 87(3):632-639. PubMed ID: 32926975
[TBL] [Abstract][Full Text] [Related]
24. Management of immune checkpoint inhibitor-related dermatologic adverse events.
Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
[TBL] [Abstract][Full Text] [Related]
25. Toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Orphanet J Rare Dis; 2010 Dec; 5():39. PubMed ID: 21162721
[TBL] [Abstract][Full Text] [Related]
26. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.
Pach J; Valido K; Belzer A; Leventhal JS
Am J Clin Dermatol; 2024 Jul; 25(4):595-607. PubMed ID: 38767827
[TBL] [Abstract][Full Text] [Related]
27. Detecting Lesional Granulysin Levels for Rapid Diagnosis of Cytotoxic T lymphocyte-Mediated Bullous Skin Disorders.
Chen CB; Kuo KL; Wang CW; Lu CW; Chung-Yee Hui R; Lu KL; Chang WC; Chen WT; Yun F; Teng YC; Lee HE; Lin JY; Ho HC; Chi MH; Yu-Wei Lin Y; Chang CJ; Lin Y; Ku CL; Hung SI; Chang YC; Chung WH;
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1327-1337.e3. PubMed ID: 33039642
[TBL] [Abstract][Full Text] [Related]
28. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Harr T; French LE
Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
[TBL] [Abstract][Full Text] [Related]
29. [The major SCAR syndromes].
Piérard GE; Lesuisse M; Piérard-Franchimont C
Rev Med Liege; 2017 Oct; 72(10):444-447. PubMed ID: 29058836
[TBL] [Abstract][Full Text] [Related]
30. Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options.
Paulmann M; Mockenhaupt M
Curr Pharm Des; 2016; 22(45):6852-6861. PubMed ID: 27779083
[TBL] [Abstract][Full Text] [Related]
31. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
[TBL] [Abstract][Full Text] [Related]
32. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
Mustafa SS; Ostrov D; Yerly D
Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
[TBL] [Abstract][Full Text] [Related]
33. [Drug reaction with eosinophilia and systemic symptoms].
Tehrany YA; Laffitte E; Grosgurin O; Spoerl D
Rev Med Suisse; 2016 Apr; 12(513):684-6, 688-90. PubMed ID: 27197323
[TBL] [Abstract][Full Text] [Related]
34. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management.
Mockenhaupt M
Semin Cutan Med Surg; 2014 Mar; 33(1):10-6. PubMed ID: 25037254
[TBL] [Abstract][Full Text] [Related]
35. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).
Torres-Navarro I; de Unamuno-Bustos B; Botella-Estrada R
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):607-614. PubMed ID: 32846030
[TBL] [Abstract][Full Text] [Related]
36. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).
Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D
Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956
[TBL] [Abstract][Full Text] [Related]
37. Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review.
Weinkle A; Pettit C; Jani A; Keller J; Lu Y; Malachowski S; Trinidad JC; Kaffenberger BH; Ergen EN; Hughey LC; Smith D; Seminario-Vidal L
J Am Acad Dermatol; 2019 Sep; 81(3):749-757. PubMed ID: 31150704
[TBL] [Abstract][Full Text] [Related]
38. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
[TBL] [Abstract][Full Text] [Related]
39. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Wolkenstein P; Chosidow O; Fléchet ML; Robbiola O; Paul M; Dumé L; Revuz J; Roujeau JC
Contact Dermatitis; 1996 Oct; 35(4):234-6. PubMed ID: 8957644
[TBL] [Abstract][Full Text] [Related]
40. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature.
van Hattem S; Beerthuizen GI; Kardaun SH
Br J Dermatol; 2014 Dec; 171(6):1539-45. PubMed ID: 24888401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
